• Protagonist Therapeutics Initiates PTG-200 Phase 1 Trial americanpharmaceuticacreview
    November 10, 2017
    Protagonist Therapeutics announced the initiation of dosing in a Phase I healthy volunteer study of PTG-200, a potential first-in-class, gastrointestinal-restricted, oral peptide interleukin (IL)-23 receptor antagonist.
PharmaSources Customer Service